Clinical Trial Update: Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial [Phase 4]

View source ↗

Summary

Phase 4 trial update on candesartan aimed at preventing cardiovascular events after Cypher or Taxus coronary stenting. The study status is listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Hypertension

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Kumamoto University | Conditions: Hypertension, Coronary Artery Disease | Phase 4 | Status: COMPLETED